A new generation of anti-obesity pills billed as cheaper and more convenient alternatives to weight-loss injections may impose overwhelming costs on the NHS, experts have warned.

As many as 12 anti-obesity drugs to be delivered in pill form are set to be available by 2030, according to figures obtained by The i Paper .

The first two medications – made by weight-loss market leaders Eli Lilly and Novo Nordisk – are likely to gain approval by the end of this year and hit global markets within the next 12 to 18 months.

Though pills are generally cheaper to produce than jabs, the high demand for them means makers could charge similar prices to existing injections to supply them.

As a result, it could mean that they are unlikely to be widely available on the NHS, with members of the pu

See Full Page